Abbott Laboratories Pakistan Ltd
Abbott Laboratories Pakistan Ltd operates in Pharmaceuticals.
Abbott Laboratories Pakistan Ltd (ABOT) - Total Liabilities
Latest total liabilities as of June 2024: PKRs15.26 Billion PKR
Based on the latest financial reports, Abbott Laboratories Pakistan Ltd (ABOT) has total liabilities worth PKRs15.26 Billion PKR as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Abbott Laboratories Pakistan Ltd - Total Liabilities Trend (2016–2023)
This chart illustrates how Abbott Laboratories Pakistan Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Abbott Laboratories Pakistan Ltd Competitors by Total Liabilities
The table below lists competitors of Abbott Laboratories Pakistan Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TELKOM SA SOC
MU:TZL1
|
Germany | €35.02 Billion |
|
CEA Industries Inc. Warrant
NASDAQ:CEADW
|
USA | $1.23 Million |
|
H.W.A. AG - Dusseldorf Stock Exchang
DU:H9W
|
Germany | €29.01 Million |
|
C2E Energy Inc
PINK:OOGI
|
USA | $985.04K |
|
James Fisher and Sons PLC
LSE:FSJ
|
UK | GBX324.90 Million |
Liability Composition Analysis (2016–2023)
This chart breaks down Abbott Laboratories Pakistan Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.74 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Abbott Laboratories Pakistan Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Abbott Laboratories Pakistan Ltd (2016–2023)
The table below shows the annual total liabilities of Abbott Laboratories Pakistan Ltd from 2016 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | PKRs18.46 Billion | +9.77% |
| 2022-12-31 | PKRs16.81 Billion | +49.95% |
| 2021-12-31 | PKRs11.21 Billion | +20.24% |
| 2020-12-31 | PKRs9.33 Billion | +26.36% |
| 2019-12-31 | PKRs7.38 Billion | +4.74% |
| 2018-12-31 | PKRs7.05 Billion | +44.38% |
| 2017-12-31 | PKRs4.88 Billion | +59.91% |
| 2016-12-31 | PKRs3.05 Billion | -- |